Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody Responses Against Diverse Henipaviruses
Authors:
- Thomas B. VoigtTVThomas B. Voigt
- Noor GhoshNGNoor Ghosh
- Brandon C. RosenBRBrandon C. Rosen
- Taylor NewboltTNTaylor Newbolt
- Johan J. LouwJLJohan J. Louw
- Aaron Yrizarry-MedinaAYAaron Yrizarry-Medina
- Christakis PanayiotouCPChristakis Panayiotou
- Jack T. MauterJMJack T. Mauter
- Giovana de Figueiredo GodoyGGGiovana de Figueiredo Godoy
- Joshua TeraoJTJoshua Terao
- Eva G. RakaszEREva G. Rakasz
- Matthew R. ReynoldsMRMatthew R. Reynolds
Open Access
Abstract
Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic and often lethal zoonotic viruses with broad species tropism and no approved human vaccines. The emergence of genetically divergent HNVs—including Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV)—emphasizes the need for broadly protective countermeasures. Here, we evaluated the antibody (Ab) responses to sequential mRNA vaccines encoding the membrane-bound attachment glycoprotein (gG) from NiV, GhV, and/or LayV in a pilot study with Indian rhesus macaques. Serum binding Ab responses were quantified by ELISA against five soluble gG antigens (NiV, HeV, GhV, LayV, MojV). Functional activity was assessed by neutralization assays using NiV, HeV, and GhV pseudoviruses, and by receptor-blocking ELISA. Sequential vaccination induced high-titer IgG binding against all five HNV gGs with increasing breadth after each dose. Pan-genus regimens elicited moderate neutralizing Ab titers against NiV, HeV, and GhV, whereas the NiV-only regimen elicited potent but narrow neutralization against NiV and HeV. Conversely, the GhV-LayV-GhV regimen elicited strong binding to GhV, LayV, and MojV gG and robust neutralization of GhV pseudovirus, but limited cross-reactivity to NiV and HeV. In this pilot study, we demonstrated that mRNA vaccination can elicit broadly reactive binding and neutralizing Ab responses across phylogenetically distant HNVs. Additionally, we show GhV pseudovirus neutralization for the first time. Collectively, these data provide a foundation for the development of next-generation pan-genus HNV vaccines capable of mitigating future HNV outbreaks.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI155275)
- NIH (P51OD011106)
This publication has 52 references indexed in Scilit:
- Structure and function of a pair of non-competing monoclonal antibodies against Langya henipavirus attachment glycoproteinCell Reports, 2025
- Innovations in vaccine design: Computational tools and techniques2025
- Changes to virus taxonomy and the ICTV Statutes ratified by the International Committee on Taxonomy of Viruses (2024)Archives of Virology, 2024
- Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious DiseasesBioDrugs, 2024
- Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick‐borne encephalitis and dengue virus infectionsJournal of Medical Virology, 2023
- Henipaviruses: an expanding global public health concern?GeroScience, 2022
- Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from batsCell Reports, 2022
- Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding ProteinCell, 2020
- High-Throughput Mapping of B Cell Receptor Sequences to Antigen SpecificityCell, 2019
- Long‐term neurological and functional outcome in Nipah virus infectionAnnals of Neurology, 2007